<DOC>
	<DOC>NCT02812862</DOC>
	<brief_summary>The aim of this study is to evaluate the pulmonary and cardiac effects of a LABA / LAMA combination therapy in patients suffering from both chronic heart failure and chronic obstructive pulmonary disease. The secondary aim of the study it to assess the safety of the LABA / LAMA combination.</brief_summary>
	<brief_title>Cardiac Effects of Fixed-dose Dual Bronchodilator in Patients With Heart Insufficiency and COPD</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<criteria>Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel Symptomatic with regard to dyspnea (NYHA II and more) Treatment group: COPD (FEV1/FVC ratio &lt;70%, FEV1 &lt; 80%) Control group: No COPD, no LAMA or LABA Chronic heart failure (ejection fraction &lt; 40%) Stability of CHF during the preceding 3 months Male or female aged &gt; 18 years Written informed consent prior to study participation The subject is willing and able to follow the procedures outlined in the protocol Lack of informed consent Pregnant and lactating females Acute exacerbation of COPD, acute respiratory failure (pH &lt; 7,35 and/ or respiratory rate &gt; 30/min) Unstable heart failure or planned change in medication Not symptomatic Patient has been committed to an institution by legal or regulatory order Participation in a parallel interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>